About: TOWARDS PERSONALIZED MANAGEMENT OF CHRONIC HYPERTENSION IN PREGNANCY

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: TOWARDS PERSONALIZED MANAGEMENT OF CHRONIC HYPERTENSION IN PREGNANCY Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	TOWARDS PERSONALIZED MANAGEMENT OF CHRONIC HYPERTENSION IN PREGNANCY
Creator	Magee, L Of, Dadelszen P, Towards Hypertension In, Kametas N, Von Khalil A, Personalized Management, Pregnancy,
source	Elsevier; Medline; PMC
abstract	ABSTRACT Objectives Chronic hypertension complicates 1-2% of pregnancies and it is increasingly common. Women with chronic hypertension are easily-recognized and in touch with a wide variety of healthcare providers before, during, and after pregnancy, mandating that chronic hypertension in pregnancy be within the scope of many practitioners. We reviewed recent data on management to inform current care and future research. Study design Narrative review of published literature. Results Compared with normotensive women, women with chronic hypertension are at increased risk of maternal and perinatal complications. Women wish to be involved in their care and are capable of measuring blood pressure (BP) at home. Accurate devices for home BP monitoring are now available. The diagnostic criteria for superimposed preeclampsia remain problematic, as most guidelines continue to include deteriorating BP control in the definition. It has not been established how angiogenic markers may aid in confirmation of the diagnosis of superimposed preeclampsia when suspected, over and above information provided by routinely-available clinical data and laboratory results. While chronic hypertension is a strong risk factor for preeclampsia and aspirin decreases preeclampsia risk, the effectiveness specifically among women with chronic hypertension has been questioned. It is unclear whether calcium has an independent effect in preeclampsia prevention in such women. Treating hypertension with antihypertensive therapy halves the risk of progression to severe hypertension, thrombocytopenia, and elevated liver enzymes, but a reduction in preeclampsia or serious maternal complications has not been demonstrated; however, the latter lack of evidence is possibly due to few events. Also, treating chronic hypertension neither reduces nor increases fetal/newborn death or morbidity, regardless of the gestational age at which the antihypertensive treatment is started. Antihypertensive agents are not teratogenic, but there may be an increase in malformations associated with chronic hypertension itself. At present, BP treatment targets used in clinic are the same as those used at home; although BP values tend to be inconsistently lower at home among hypertensive women. While starting all women on the same antihypertensive medication is usually effective in reducing BP, it remains unclear whether there is an optimal agent for such an approach, or how best to use combinations of antihypertensive medications. An alternative approach is to individualize care, using maternal characteristics and BP features beyond BP level (e.g., variability) that are of prognostic value. Outcomes may be improved by timed birth between 38+0-39+6 weeks based on observational literature; confirmatory trial evidence is pending. Postnatal care is facilitated by the acceptability of most antihypertensives (included angiotensin converting enzymes inhibitors) for use in breastfeeding. Conclusions The evidence base to guide the care of pregnant women with chronic hypertension is growing and aligning international guidance. Addressing outstanding research questions would inform personalized care of chronic hypertension in pregnancy.
has issue date	2020-07-18(xsd:dateTime)
bibo:doi	10.1016/j.ajog.2020.07.026
bibo:pmid	32687817
has license	els-covid
sha1sum (hex)	4d4546e00bbf11879bc766e308befc8bf36fbf6c
schema:url	https://doi.org/10.1016/j.ajog.2020.07.026
resource representing a document's title	TOWARDS PERSONALIZED MANAGEMENT OF CHRONIC HYPERTENSION IN PREGNANCY
has PubMed Central identifier	PMC7367795
has PubMed identifier	32687817
schema:publication	Am J Obstet Gynecol
resource representing a document's body	covid:4d4546e00bbf11879bc766e308befc8bf36fbf6c#body_text
is schema:about of	named entity 'Journal' named entity 'pregnancy' named entity 'physiological' named entity 'hypotension' named entity 'hydralazine' named entity 'pregnancy' named entity 'SMFM' named entity 'antihypertensives' named entity 'hemodynamic' named entity 'ACEIs' named entity 'preeclampsia' named entity 'healthcare providers' named entity 'hydralazine' named entity 'Black race' named entity 'stage 2' named entity 'birthweight' named entity 'nifedipine' named entity 'growth velocity' named entity 'nifedipine' named entity 'labetalol' named entity 'randomised trials' named entity 'Poland' named entity 'observational study' named entity 'abruption' named entity 'hypertension' named entity 'preeclampsia' named entity 'pregnancy' named entity 'clinical practice' named entity 'chronic hypertension' named entity 'labetalol' named entity 'antihypertensive agents' named entity 'spironolactone' named entity 'risk factors' named entity 'hypertension' named entity 'cocaine' named entity 'Cushing syndrome' named entity 'American College of Cardiology' named entity 'work-up' named entity 'physiological' named entity 'renin' named entity 'stage 1' named entity 'hydralazine' named entity 'contraindication' named entity 'quantifies the risk' named entity 'hypertension' named entity 'mmHg' named entity 'meta-analysis' named entity 'demographic' named entity 'pre-eclampsia' named entity 'Atenolol' named entity 'anti-androgen' named entity 'Early pregnancy' named entity 'calcium channel blockers' named entity 'chronic hypertension' named entity 'abruption' named entity 'ACEIs' named entity 'fetal heart rate' named entity 'hypertension' named entity 'Pregnancy' named entity 'antihypertensive agents' named entity 'hypertension' named entity 'placental' named entity 'network meta-analysis' named entity 'cohort studies' named entity 'pindolol' named entity 'hypertension in pregnancy' named entity 'antidepressants' named entity 'chest pain' named entity 'ACEIs' named entity 'antihypertensive' named entity 'Home blood pressure monitoring' named entity 'COVID-19 pandemic' named entity 'pregnancy' named entity 'Preeclampsia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software